Compare Hasbro, Inc. (HAS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Hasbro, Inc. trades at $97.28 (market cap $13.69B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.4× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 2.89% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HAS | IDXX | |
|---|---|---|
Market Cap | $13.69B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $766.68 |
52-Week Low | $70.95 | $526.44 |
Enterprise Value | $15.88B | $47.12B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.915, up 0.45% on the day, with a bullish technical outlook and strong earnings beats in recent quarters. The stock shows robust profitability with a 64.41% gross margin and 167.83% ROE, though 2025 net income was negative. Analyst consensus is a Buy with a $104.90 price target, and recent news highlights growth in Magic: The Gathering and new content launches.
Outlook is positive driven by franchise strength and digital gaming, but risks include margin pressures, high debt, and competitive threats. The stock offers a 2.93% dividend yield and is near its 52-week high, suggesting cautious optimism for continued upside if execution remains solid.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
